XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer
Objective: Polymorphisms in XPG were considered to contribute to the clinical outcome of patients receiving platinum drug chemotherapy. We investigated the impact of several potential SNPs of XPG on the efficacy of platinum-based chemotherapy in NSCLC patients.
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Professional Medical Publicaitons
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3809298/ |